Cancer Family
Malignant Skin Neoplasm
CI-CAN-00000250Explore in graph →
320 active trials14 approved drugs64 evidence items
- NCIt
- C2920
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000250Explore in graph →
Clinical trials
1,248 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (202)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01258855 | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | May 10, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02690948 | Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer | completed | Phase 1 / Phase 2 | 16 | Anne ChangOTHER | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02941744 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases(ipniv) | completed | Phase 1 / Phase 2 | 56 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT00038025 | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT00788775 | Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT01108094 | Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas | completed | Phase 2 | 29 | Stanford UniversityOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT00038376 | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00243061 | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01791894 | Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma(ATO) | completed | Phase 1 / Phase 2 | 5 | Stanford UniversityOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00804908 | A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma | completed | Phase 2 | 346 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jun 6, 2018 | clinicaltrials |
| NCT02550678 | A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma(ASN-002-001) | completed | Phase 1 / Phase 2 | 16 | Ascend Biopharmaceuticals LtdINDUSTRY | 1 | Jun 6, 2018 | clinicaltrials |
| NCT03541148 | Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma | completed | Phase 2 | 20 | Catalysis SLINDUSTRY | 1 | May 30, 2018 | clinicaltrials |
| NCT00961220 | O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT02007317 | Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study | completed | Phase 2 | 30 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT00387751 | Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00073918 | Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 111 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT01359735 | Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients | completed | Phase 2 | 8 | HealthpointINDUSTRY | 1 | Jun 29, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00397982 | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma(Mel47) | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01395121 | A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread(NICAM) | completed | Phase 2 | 29 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00244855 | Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma | completed | Phase 2 | 32 | Fred Hutchinson Cancer CenterOTHER | 1 | May 22, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00007345 | Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | completed | Phase 2 | 131 | National Cancer Institute (NCI)NIH | 2 | May 16, 2017 | clinicaltrials |
| NCT00091559 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 5, 2017 | clinicaltrials |
| NCT01396070 | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | completed | Phase 2 | 36 | Youn KimOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00424515 | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma(BUS255) | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00577382 | SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | completed | Phase 2 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00611208 | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 2 | 32 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 29, 2016 | clinicaltrials |
| NCT00026221 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01325688 | PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities | completed | Phase 2 | 75 | PeplinINDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00178841 | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | completed | Phase 2 | 4 | Vanderbilt UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00432185 | To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC | completed | Phase 2 | 117 | PeplinINDUSTRY | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00783965 | Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back | completed | Phase 2 | 34 | UCSF Benioff Children's Hospital OaklandOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00588341 | Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection | completed | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT00089180 | T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00923195 | Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00665470 | Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2019source: clinicaltrials